Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Catalent Collaborates with MGB Biopharma to Provide Accelerated Formulation and Supply Services for Phase 2 Clinical Trial Materials

Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it welcomed the commencement of Phase 2 clinical trials of MGB Biopharma.

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

The two companies have collaborated to accelerate the drug formulation, manufacture and distribution of MGB Biopharma’s leading candidate, MGB-BP-3, an orally-dosed drug targeting the eradication of Clostridium difficile-associated diarrhea (CDAD).

Catalent’s services focused on the rapid development of a new tablet formulation and leveraged its clinical supply network to distribute the resultant products for use in a U.S. Phase 2a trial. By streamlining activities, and running multiple parallel processes with minimal downtime, Catalent has quickly developed a superior formulation to optimize this molecule and solved complex clinical trial logistics challenges, completing the project in just six months.

The project combined a team of experts at Catalent’s early phase development center of excellence in San Diego who performed the formulation and clinical material manufacturing, alongside clinical supply specialists at its Kansas City, Missouri facility and Canadian supply depot, and Gary W. Goodson, of Cornerstone Pharma Consulting LLC, a chemistry, manufacturing and controls consultant, who provided further specialist technical support.

The project presented us with an incredibly challenging timeline that separate formulation and clinical supply vendors would have been unable to achieve,” commented Julien Meissonnier, Catalent’s Vice President, Science & Technology. “By gathering our formulation, analytical and clinical supply experts under a single project team from the start, and leveraging Catalent’s common systems and processes across our drug product and clinical supply sites, our team has succeeded in ensuring that MGB Biopharma’s drug product was delivered to the first patients on time.”

Catalent’s San Diego facility is one of three global centers of excellence in early-phase development focusing on preclinical to clinical Phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules, the other two being located in Somerset, New Jersey and Nottingham, U.K. The three strategically located sites are closely connected to the company’s clinical supply services network, to optimize the transition from finished dose manufacture to clinical packaging and distribution.

Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
Researched List: Blister Machines for Life Sciences
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report